Atara biotherapeutics reports inducement grant under nasdaq listing rule 5635(c)(4)

Thousand oaks, calif.--( business wire )--atara biotherapeutics, inc. (nasdaq: atra), a leader in t-cell immunotherapy, leveraging its novel allogeneic epstein-barr virus (ebv) t-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported the grant of 66,800 restricted stock units of atara's common stock to six newly hired employees and stock options to purchase an aggregate of 40,000 shares of atara's common stock to one such newly hired employee. these awards were approved by the compensation committee of atara's board of directors and granted under the atara biotherapeutics, inc. 2018 inducement plan, with a grant date of january 3, 2022, as an inducement material to the new employee entering into employment with atara, in accordance with nasdaq listing rule 5635(c)(4).
ATRA Ratings Summary
ATRA Quant Ranking